Nine contemporary therapeutic directions in heart failure.
heart failure
heart failure treatment
left ventricular assist device
Journal
Heart Asia
ISSN: 1759-1104
Titre abrégé: Heart Asia
Pays: England
ID NLM: 101542742
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
02
2019
revised:
08
02
2019
accepted:
11
02
2019
entrez:
30
4
2019
pubmed:
30
4
2019
medline:
30
4
2019
Statut:
epublish
Résumé
The global burden of heart failure has continued to increase dramatically with 26 million people affected and an estimated health expenditure of $31 billion worldwide. Several practice-influencing studies were reported recently, bringing advances along many frontiers in heart failure, particularly heart failure with reduced ejection fraction. In this article, we discuss nine distinct therapeutic areas that were significantly influenced by this scientific progress. These distinct areas include the emergence of sodium-glucose cotransporter-2 inhibitors, broadening the application of angiotensin-neprilysin inhibition, clinical considerations in therapy withdrawal in those patients with heart failure that 'recover' myocardial function, benefits of low-dose direct oral anticoagulants in sinus rhythm, targeted therapy for treating cardiac amyloidosis, usefulness of mitral valve repair in heart failure, the advent of newer left ventricular assist devices for advanced heart failure, the role of ablation in atrial fibrillation in heart failure, and finally the use of wearable defibrillators to address sudden death.
Identifiants
pubmed: 31031834
doi: 10.1136/heartasia-2018-011150
pii: heartasia-2018-011150
pmc: PMC6454326
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e011150Déclaration de conflit d'intérêts
Competing interests: MV is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (NIH/NCATS Award UL 1TR002541), and serves on the advisory boards for AstraZeneca, Bayer AG and Baxter Healthcare. MP serves on an advisory board for AstraZeneca and has received speaker honoraria from AstraZeneca, Bayer and Boehringer Ingelheim. MM is a consultant for Abbott, Medtronic, Janssen (a division of Johnson and Johnson), Mesoblast, NupulseCV, Bayer, FineHeart, Xogenex and Portola.
Références
N Engl J Med. 1999 Dec 16;341(25):1882-90
pubmed: 10601507
Eur J Heart Fail. 1999 Dec;1(4):419-23
pubmed: 10937957
N Engl J Med. 2002 Mar 21;346(12):877-83
pubmed: 11907286
Circulation. 2003 Jun 17;107(23):2920-5
pubmed: 12771006
Am Heart J. 2004 Jul;148(1):157-64
pubmed: 15215806
N Engl J Med. 2004 Dec 9;351(24):2481-8
pubmed: 15590950
N Engl J Med. 2005 Jun 23;352(25):2581-8
pubmed: 15972864
JAMA. 2007 Mar 28;297(12):1319-31
pubmed: 17384437
N Engl J Med. 2007 Jun 14;356(24):2457-71
pubmed: 17517853
Ann Intern Med. 2007 Aug 7;147(3):149-55
pubmed: 17576993
N Engl J Med. 2009 Oct 8;361(15):1427-36
pubmed: 19812399
Nat Rev Cardiol. 2010 Jul;7(7):398-408
pubmed: 20479782
J Card Fail. 2011 Jul;17(7):527-32
pubmed: 21703523
N Engl J Med. 2012 May 17;366(20):1859-69
pubmed: 22551105
Neurology. 2012 Aug 21;79(8):785-92
pubmed: 22843282
N Engl J Med. 2012 Oct 25;367(17):1587-95
pubmed: 23094720
Int J Cardiol. 2013 Sep 1;167(5):1772-82
pubmed: 23298559
J Am Heart Assoc. 2013 Apr 22;2(2):e000098
pubmed: 23608605
Circulation. 2014 Feb 4;129(5):587-97
pubmed: 24334175
J Am Coll Cardiol. 2014 Apr 1;63(12):1123-1133
pubmed: 24491689
J Heart Lung Transplant. 2014 Jul;33(7):667-74
pubmed: 24721183
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
Eur Heart J. 2015 Jun 14;36(23):1454-62
pubmed: 25825043
Am Heart J. 2015 Aug;170(2):298-305
pubmed: 26299227
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Am Health Drug Benefits. 2015 Sep;8(6):330-4
pubmed: 26557227
Eur Heart J. 2016 May 14;37(19):1526-34
pubmed: 26819227
N Engl J Med. 2016 Jun 9;374(23):2235-45
pubmed: 27042964
N Engl J Med. 2016 Apr 21;374(16):1521-32
pubmed: 27043774
Circulation. 2016 Sep 6;134(10):752-72
pubmed: 27470878
N Engl J Med. 2017 Feb 2;376(5):440-450
pubmed: 27959709
J Am Coll Cardiol. 2017 Jul 11;70(2):252-289
pubmed: 28315732
N Engl J Med. 2017 May 18;376(20):1956-1964
pubmed: 28402745
J Am Coll Cardiol. 2017 May 30;69(21):2646-2656
pubmed: 28545639
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Circ Heart Fail. 2017 Jun;10(6):null
pubmed: 28611125
ESC Heart Fail. 2014 Sep;1(1):4-25
pubmed: 28834669
JAMA Cardiol. 2017 Oct 1;2(10):1130-1139
pubmed: 28877291
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
J Heart Lung Transplant. 2017 Oct;36(10):1080-1086
pubmed: 28942782
Eur Heart J. 2018 Feb 1;39(5):363-370
pubmed: 29020355
N Engl J Med. 2018 Feb 01;378(5):417-427
pubmed: 29385358
N Engl J Med. 2018 Apr 12;378(15):1386-1395
pubmed: 29526139
Circulation. 2018 Jul 31;138(5):458-468
pubmed: 29526832
Eur Heart J. 2018 May 21;39(20):1781-1783
pubmed: 29579180
Circulation. 2018 Oct 30;138(18):1923-1934
pubmed: 29807933
N Engl J Med. 2018 Jul 5;379(1):11-21
pubmed: 29972753
N Engl J Med. 2018 Jul 05;379(1):22-31
pubmed: 29972757
Am Heart J. 2018 Nov;205:1-11
pubmed: 30134187
N Engl J Med. 2018 Dec 13;379(24):2297-2306
pubmed: 30145927
N Engl J Med. 2018 Sep 13;379(11):1007-1016
pubmed: 30145929
N Engl J Med. 2018 Oct 4;379(14):1332-1342
pubmed: 30146935
J Heart Lung Transplant. 2018 Nov;37(11):1281-1284
pubmed: 30245150
N Engl J Med. 2018 Sep 27;379(13):1205-1215
pubmed: 30280654
Diabetologia. 2018 Dec;61(12):2461-2498
pubmed: 30288571
Am J Cardiol. 2018 Dec 1;122(11):1896-1901
pubmed: 30340765
JACC Heart Fail. 2019 Jan;7(1):1-12
pubmed: 30414818
N Engl J Med. 2019 Feb 7;380(6):539-548
pubmed: 30415601
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
Lancet. 2019 Jan 5;393(10166):61-73
pubmed: 30429050
N Engl J Med. 2018 Dec 13;379(24):2374-2376
pubmed: 30575469
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
N Engl J Med. 1996 Dec 26;335(26):1933-40
pubmed: 8960472